Author

C. Wang

Institution: Eli Lilly (United States)

Observed institutions: Eli Lilly (United States), HUTCHMED (China) Limited (China)

OpenAlex ID: A5070971304

Genomic Evolution and Resistance to Pirtobrutinib in Covalent Btk‐inhibitor Pre‐treated Chronic Lymphocytic Leukemia Patients: Results From the Phase I/ii Bruin Study

2023 · K. Patel, J. R. Brown, et al. · Hematological Oncology · 4

Pirtobrutinib in Covalent Btk‐inhibitor Pre‐treated Mantle Cell Lymphoma: Updated Results, Subgroup Analysis From Bruin With >3 Years Follow‐up From Start of Enrollment

2023 · C. Y. Cheah, N. N. Shah, et al. · Hematological Oncology · 1

Pb1862: Bruin Cll-313: a Phase 3 Open-label, Randomized Study of Pirtobrutinib Vs Bendamustine+rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (trial in Progress)

2022 · W. Jurczak, C. Dartigeas, et al. · HemaSphere · 1

Pb1880: a Multicenter Phase 1 Study Evaluating the Safety and Tolerability of Hmpl-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma or Other Non-hodgkin Lymphoma

2022 · B. Kahl, J. Cohen, et al. · HemaSphere

Works count: 4

Citation count: 6

H-index: 1

I10-index: